Press Release: ValenzaBio : ValenzaBio Announces Positive Preliminary Data from Phase 1b/2a Trial of VB119, an Anti-CD19 Monoclonal Antibody for the Treatment of Primary Membranous Nephropathy

BETHESDA, Md.--(BUSINESS WIRE)--ValenzaBio, Inc., a biopharmaceutical company developing monoclonal antibody (mAb) therapeutics for autoimmune and inflammatory indications, today announced positive initial results from its open label Phase 1a/2b clinical trial of VB119, a B-cell depleting mAb with enhanced antibody-dependent cellular cytotoxicity and potent binding to CD19, for the treatment of primary membranous nephropathy (PMN). These data represent the first clinical proof-of-concept for an